Human immunodeficiency virus (HIV) integrase inhibitors are increasingly being used for antiretroviral therapy (ART), and dolutegravir (DTG/Tivicay) has emerged as a leading core agent. In 2018, the Tsepamo study reported a 6-to 9-fold increase for neural tube defect (NTD) risk among the offspring of mothers receiving DTG during early gestation. Maternal folate (vitamin B9) status is the largest known modifier of NTD risk, so we evaluated folate-related mechanisms of action and the critical period for DTG developmental toxicity. Folate receptor (FOLR1) binding studies indicate DTG is a non-competitive FOLR1 antagonist at therapeutic concentrations. In vitro testing indicates calcium (2mM) increases FOLR1-folate interactions and alters DTG-FOLR1-folate interactions and cytotoxicity. DTG does not inhibit downstream folate metabolism by dihydrofolate reductase (DHFR). Early embryonic exposure to
modifier for NTD risk is folate (vitamin B9) status, so pregnant women and women of child bearing age are advised by the World Health Organization (WHO) and the US Public Health Service (USPHS) to take supplemental folic acid (FA) to ensure a daily intake of 400µg [5] [6] [7] [8] . Folic acid is a water-soluble provitamin that is transformed to bioactive forms of folate in vivo 9 . Reduced forms of folate such as Leucovorin, also known as 5-formyltetrahydrofolate (folinic acid, SFA), or 5-methyltetrahydrofolate (Metafolin, 5-CH are active forms and do not require enzymatic reduction by dihydrofolate reductase (DHFR) to enter the folate cycle 10, 11 . Both SFA and 5-CH 3 -THF are naturally occurring in humans, but 5-CH 3 -THF is the predominate form of folate in cerebral spinal fluid, blood serum, and erythrocytes 11, 12 . Pre-conceptional FA supplementation to women of childbearing age can decrease the occurrence of NTDs by up to 85 percent 13, 14 . The daily recommended dose of 400µg is reported to provide sufficient FA to produce optimal serum and red blood cell (RBC) folate concentrations in pregnant women 15, 16 . Unfortunately, FA supplementation started after the first trimester of pregnancy, does not prevent NTDs. In response to this concern, FA fortification of grains and cereal products has been mandatory in the United States since 1999, and post-fortification monitoring indicates that this has been effective in decreasing the occurrence of NTDs [17] [18] [19] . Initially isolated from human placenta, the folate receptor isoforms have been shown to have tissuespecific and cell-specific expression patterns [20] [21] [22] [23] . The folate receptor isoforms are externally bound to the plasma membrane by glycosyl-phosphatidylinositol (GPI) anchors, but a high-affinity folate receptor has also been observed unbound without GPI modifications in plasma. Folate binding data and immunodetection of FOLR1/FR-α indicates expression is primarily found in the plasma, placenta, choroid plexus, and the brush border membranes of the kidney 24, 25 . In the developing mouse embryo, Folr1 is essential for embryonic and neural tube development 26 , and Folr1 is observed to be highly expressed in yolk sac, neural folds, and the neural tube 27 . The Folr2 protein is non-essential for development in mice, as Folr2 knockout mice develop normally 26 , and human FOLR3 lacks a mouse homolog. FOLR4/FR-δ, also known as Juno, is a member of the folate receptor family but is not involved in folate uptake 28 . JUNO is located on the surface of mammalian eggs and recognizes a sperm-counterpart, IZUMO1, to facilitate fertilization 29 .
FOLR1 Antagonism and Birth Defect Risks:
The developmental toxicity of anti-folates was first described in chickens 30 . Subsequent studies in mice, rats, rabbits, and monkeys demonstrated embryotoxicity and teratogenicity that varied based on developmental timing and dose [31] [32] [33] . Anti-folate, e.g. methotrexate (MTX), developmental toxicity and the mitigation or rescue by supplemental folate has been demonstrated in experimental animals and in clinical practice, respectively 34, 35 . As immunotherapy began to also target FOLR1-positve tumors, antibodies against FOLR1/ FRα were reported to antagonize or block cellular folate uptake into placenta cells 36, 37 . The initial report of FOLR1 autoantibodies examined FOLR1 antiserum on embryogenesis in a rat model. It was demonstrated that antiserum against FOLR1/FRα and FOLR2/FRβ caused dose-dependent developmental toxicity 36 . Large doses of antiserum caused 100% embryo-lethality, while lower doses increased the incidence of NTDs in exposed offspring. Autoantibody directed against human FOLR1/ FRα were also detected in human serum in association with an increased risk of NTDs 37 . We developed a sensitive assay to identify FOLR1-folate binding interactions with autoantibodies 38 . Since the initial report, we have examined several population cohorts and have found that autoantibodies to FOLR1 are significantly higher in NTD-affected pregnancies compared to control subjects, supporting the association between FOLR1 autoantibodies in maternal serum and increased risk of folate-responsive birth defects, including NTDs, in expectant mothers [39] [40] [41] .
DTG and FOLR1 Antagonism:
Based on the clinical benefit of FA in the prevention of birth defects in humans, the utility of folates in rescuing embryo lethality and NTDs in FOLR1 mutant mice 26, 42 , and the risk of NTDs with DTG exposure or FOLR1 antagonism, we hypothesized that DTG is a FOLR1 antagonist. This report represents the first published data on the testing of antagonism of FOLR1-folate binding by DTG. It utilizes a vertebrate animal model (Danio rerio) to evaluate folic acid as a major modifier of DTG-induced developmental toxicity. Developmental toxicity testing of antifolates directly on pregnant women is medically unethical, so an in vitro cellular model (HTR-8/SVneo) was used to study human placental-trophoblast interactions with folate in the presence of DTG. Although various cell types are recognized in embryonic placenta primordia and term placentas, trophoblasts were selected for testing, because they perform several essential functions for viviparous development, have essential roles in folate uptake, protect the embryo/fetus from the immune system and chemical insults, and provide bidirectional nutrient/waste flow required for embryonic and fetal growth, development, and maturation [43] [44] [45] . These experimental models allowed for the rapid determination of DTG-induced developmental toxicity and are of critical importance to the HIV, ART, and birth defect research communities. Complex timedependent protein-ligand-drug interactions modify embryo susceptibility to the developmental toxicity of DTG. The identification of these biochemical interactions and resultant developmental toxicity has clinical and biological significance beyond this report, as the results from these studies are expected to inform and guide future animal models and clinical studies of DTG-based ART in women of childbearing age. Results indicate that 1.5 ng/mL of folic acid is the equivalent inhibition produced by approximately 50ng/mL of 5-CH 3 -THF with FRα /FOLR1 (Supplemental Table 1 ). It is important to note that the predominate folate in biological fluids and tissues is 5-CH 3 THF (5-15 ng/mL), and the comparable IC 50 of 1.5ng/mL FA is equivalent to approximately 50ng/mL 5-CH 3 -THF.
RESULTS

Standard
The DHFR enzyme activity assay was performed, and the resulting absorbance (340nm) reading Table 2 ). In contrast, limited developmental toxicity was observed when exposure began during gastrulation (6-8 hpf) ( Figure   6 ). The specificity of DTG developmental toxicity was tested via rescue of DTG-induced developmental toxicity by supplemental folate (Figure 6 , Supplemental Table 2 ). When DTG exposure started at 1 or 3 hpf, high developmental toxicity (80-100%) was observed at 24 hpf. Developmental toxicity was rescued by co-exposure to folate (0-7.69% mortality). When DTG exposure started at 5 or 6-8 hpf, developmental toxicity decreased as hpf increased, with the lowest toxicity at 6-8 hpf ( Figure 6 ).
DISCUSSION
Folic acid fortification and supplementation are the major nutritional modifiers for NTD risk reduction. The function of FOLR1 is essential to embryonic development, neurodevelopment, and neural tube closure. however, FA is a higher affinity ligand for folate receptors than other folates. Whether other folates (e.g. SFA or 5-CH 3 -THF) can rescue DTG developmental toxicity and with potentially greater efficacy is unknown, but it is expected that the IC 50 results (Supplemental Table 1 ) based on relative competitive binding to FOLR1 will correlate with concentrations needed to rescue DTG developmental toxicity. Based on binding data, consistent findings of increased mortality in zebrafish embryos exposed to DTG, and rescue of DTG developmental toxicity by FA, we conclude that DTG is teratogenic due to FOLR1 antagonism.
We utilized human placental trophoblast cells (HTR-8/SVneo) exposed to DTG at clinically relevant concentrations as an in vitro model of first trimester placental cell interactions with DTG and folate.
Adverse interactions with DTG have been reported clinically with co-administered polyvalent cations, including calcium and iron (Tivicay, 09/2018, Summary of Effect of Coadministered Drugs on the Pharmacokinetics of Dolutegravir). The clinical concern is that co-administration can result in decreased DTG uptake and lower serum concentrations 48 . The increase of folate binding in cells was unexpected based on the FOLR1-folate binding microtiter assay. The increase in folate-FOLR1 interactions (+42.3%) produced by calcium alone appears biologically relevant to folate-FOLR1 interactions. This interaction is supported by another report that indicated calcium chloride (1mM) resulted in doubling of folate binding to rat intestinal mucosal cells 49 . Based on a red blood cell study that reported DTG produces cytotoxicity in the presence of extracellular calcium 50 , we focused on calcium as a modifier of folate binding in HTR- (Figure 3 ). Based on these data, we propose the increase in FOLR1-folate binding in cells exposed to DTG is due to DTG binding of calcium, and calcium-responsive At 24 hpf, most DTG exposed embryos were dead clumps of cells, so future studies may also consider looking at DTG-induced zebrafish phenotypes in greater detail to precisely determine which cell populations are affected and when pathologies or malformations occur. We observed that when exposure began during gastrulation (6-8hrs post-fertilization), there was decreased developmental toxicity ( Figure   6 ). This result is consistent with and supports the principle of a critical period for developmental toxicity (1-4 hours, or < 6-8 hours post fertilization). Wilson indicated, "susceptibility to teratogenesis varies with the developmental stage at the time of exposure to an adverse influence" 51 . The critical period of exposure/toxicity to early embryos is also consistent with clinical reports on DTG with increased risk for These data may also partial explain the lack of statistically significant preclinical teratogenicity.
Specifically, in rats and rabbits, DTG was administered during organogenesis, days 6-17 and 6-18, respectively. This is consistent with Guidelines for Industry (FDA) and guidelines put forth by the International Conference on Harmonization, but a critical period from 1-4 hours in zebrafish parallels the blastula, pre-gastrulation, pre-implantation and implantation periods of mammalian embryonic development (< 3-weeks in humans, <6.0 days post conception in mice and rats).
The mechanisms by which NTDs and congenital malformations are produced are varied, but folate antagonism is an accepted teratogenic mechanism of action in animal models and humans 52, 53 . During our review of preclinical studies, we found there was an NTD in the preclinical study at 40 mg per Kg DTG in rabbits (Oral Study for Effects of S-349572 Sodium on Embryofetal Development in Rabbits).
While one affected fetus or litter in a teratology study is not statistically significant, it is worth mentioning due to recent human studies. We propose the combination of fortified folate diets coupled to a critical period in zebrafish that parallels pre-implantation, implantation, and early gastrulation stages in mammalian embryos (Carnegie Stage < 8) limited previous detection of developmental toxicity.
We present the specificity of DTG developmental toxicity by rescue with folic acid, which is known to be effective in folate responsive anemia, increasing average serum folate, and decreasing NTD risk. The FA rescue of DTG developmental toxicity was proposed because FA has the highest affinity to FRs (Supplemental Table 1 ) and is commonly used in food fortification strategies. Clinically, SFA is preferred to decrease the anti-folate toxicity of MTX, because the use of SFA bypasses DHFR activity, which is inhibited by antifolates/FOLR1 antagonists. However, we determined that unlike known antifolates, DTG does not inhibit DHFR (Figure 4 ). Collectively, these data are consistent with partial antagonist activity at FOLR1, such that the binding of FOLR1 is altered but still interacts with FA in the presence of DTG, but the folate binding and enzymatic activity of DHFR is unchanged by DTG. Accordingly, DTG is not proposed to directly interact with folate or the binding domain of FOLR1 or DHFR, but additional structural analysis will be needed to identify and provide the location for the antagonist-protein interaction between DTG and FOLR1.
We have previously reported that homozygous deletion of Folr1 in mice is lethal, but folate supplementation of Folr1 mutants produces a range of developmental defects that vary by genetic background and range from lethality, to NTDs, to complete rescue 26, 42 . Based on these results, we propose the recommended FA (2-3 mg/kg) content in laboratory animal chow masked the developmental toxicity of DTG. We propose future mammalian animal testing of DTG developmental toxicity is warranted, but pre-, peri-, and post-implantation DTG exposure should be explored in studies using both low-folate diet (e.g. 0.3 mg/kg) and standard-folate diet to examine folate responsive defects and folate masking of DTG developmental toxicity. Furthermore, as more human cohort data is generated, or additional clinical studies are performed on DTG, biological interactions and clinical correlations between natural folate intake, folic acid fortified diets, supplemental folate, calcium intake, and resultant DTG, folate, and calcium in blood and serum and should be investigated. It has been previously reported that in human populations where folate fortification is in place, the prevalence of folate deficiency is approximately 0.1% or 1 per 1,000 individuals, but in unfortified population, the base line incidence may be > 20%, 1 in 5, or possibly higher 54 . This 100 to 200-fold difference in the incidence of folate deficiency lowers the average serum folate, increases NTD risk, and may also increase the risk of NTDs associated with early gestational in utero DTG exposure. According to a WHO review from 1993 to 2005, 42% of pregnant women had iron-folate related anemias worldwide and almost 90% of anemic women reside in Africa or Asia 55 . On the other hand, preclinical animal studies are expected to approach 0% folate-deficient on standard diets, because they all have adequate folate intake. The fortification of enriched cereal-grain products (mandatory in the U.S. on January 1, 1998) was intended to increase folate intake among childbearing-aged women to reduce their risk of NTD-affected pregnancies, but vitamins and minerals can also mitigate other environmental and pharmaceutical toxicities. The data reported in this study indicate that the research and medical communities should consider folic acid supplementation and maternal folate status as a major modifier of DTG-induced developmental toxicity.
METHODS
Folate Binding Assays:
A microtiter binding assay was used to measure inhibition of FOLR1-folate binding by DTG, as previously described for FOLR1 autoantibody 38, 41 . Briefly, FOLR1 (1 µL at 50ng/µL) was immobilized on microtiter plates in bicarbonate buffer (50mM, pH 9.0). The following day, unbound protein is removed by washing thrice with tris-buffered saline (pH 7.6). Ligand in the form of FA is used to compete with labeled (e.g. horse radish peroxidase) folic acid (FA-HRP) for competitive binding to DHFR activity and screening of DHFR inhibitors testing was examined using the Dihydrofolate Reductase Assay Kit (Sigma). The assay is based on the ability of DHFR to catalyze the reversible nicotinamide adenine dinucleotide phosphate (NADPH) dependent reduction of DHF to THF. The reaction progress is followed by monitoring the decrease in concentration of NADPH by absorbance at 340 nm in the presence of enzymes and substrates: DHF + NADPH + H+ ↔ THF + NADP+. The kit included MTX as a positive control, and the assays were performed as described by the manufacturer.
In vivo Testing of DTG Development Toxicity in Zebrafish:
Adult zebrafish were raised at 28.5°C on a 14-h light, 10-h dark cycle using an Aquaneering recirculating water system (Aquaneering, Inc., San Diego, CA). All zebrafish used for experiments were wild-type AB strain 57 . All procedures were approved by the BCM Institutional Animal Care and Use Committee. Adult zebrafish were allowed to spawn naturally in groups. Embryos were collected in intervals of 10 minutes to ensure precise developmental timing and staged following collection, placed in 60 cm 2 Petri dishes at a density of no more than 100 per dish in E3B media (60X E3B: 17.2g NaCl, 0.76g KCl, 2.9g CaCl 2 -2H 2 O, 2.39g MgSO 4 dissolved in 1L Milli-Q water; diluted to 1X in 9L Milli-Q water plus 100 μL 0.02% methylene blue), and then stored in an incubator at 28.5°C on a 14-h light, 10-h dark cycle until treatment.
Folate receptor expression and anti-folate toxicity has previously been examined in zebrafish embryos 58, 59 . Embryonic responses to DTG and folate were tested based on previously published MTX developmental toxicity testing in zebrafish 58 . Fertilized embryos were placed in 6-or 12-well plates (15-21 embryos/well) in 2-3 ml of embryo medium per well, followed by chemical treatment beginning at 1, 3, DTG was tested at 100 μM for preliminary experiments, which is approximately 10X C max from clinical testing. Folic acid supplementation was 60ng/mL, prepared in water at 60µg/mL and diluted to 60ng/mL in E3B for testing. Zebrafish embryo phenotypes were visually analyzed using light microscopy and scored as an average percentage of embryos with mortality or malformation out of all treated embryos 
Figure 2. Calcium Modifies Folate Binding to FOLR1 and DTG Interactions
Calcium (2mM) modified folate binding to FOLR1 in the microtiter protein-ligand binding assay. In the presence of Ca + 2 (2mM) and absence of DTG, folate receptor bound 42.3% more folate (FA-HRP). The response to DTG in the presence of 2mM Ca + 2 appeared bi-phasic. The DTG-Ca-FOLR1 interaction below 4µM increased folate binding, but at concentration above 4µM, the binding fell to 77%, or decreased -23% compared to untreated cells.
Figure 3. Calcium Alters DTG-FA-680 Interactions in HTR-8/SVneo
Images of HTR-8/SVneo cells exposed to 20µM DTG, 50nM FA-680 (red), and Hoechst 3342 (blue, live-nuclei) in buffer (1X DPBS, 1% FBS) (A) without additional Ca + 2 or (B) with 2mM Ca + 2 for 1 hour. Bar = 200µm. After 24hrs in RPMI (1% FBS, 50nM FA-680) and variable concentrations of DTG, nuclei showed DTG dependent (C) nuclear contraction (* P = 0.0285, **** P < 0.0001) and (D) decreased cell counts (r = -0.9318, R 2 = 0.8683, P < 0.0001, dotted lines show 95% confidence interval).
Figure 4. DHFR Activity in the Presence of MTX or DTG
DHFR catalyzed NADPH-dependent reduction of DHF to THF, reducing 340nM optical density (Y-axis, OD) readings over time (X-axis, seconds) to produce enzyme kinetics (linear slope). The initial OD reading was set to 1 OD, and the average OD change for each treatment over time was used to calculate the linear-fit equation. A) In the absence of an inhibitor, the reaction proceeded with a slope of -0.003 (OD/seconds). B) MTX (100µM) showed inhibition of DHFR activity, as observed by a slope approaching zero (-5e-05). All DTG concentrations (100-12.5µM) tested resulted in an enzymatic slope comparable to those observed in the negative control (-0.003) and are consistent with no DHFR inhibition. The critical window of exposure for DTG was determined over time by testing the start of DTG exposure at different times (1, 3, 5, and 6-8 hpf). For analysis, the 6-8 hpf range was plot at 7hpf. The normal phenotype (% normal, A) and mortality-morbidity (% dead or deformed, B) observed at 24 hpf was plot as a function of DTG treatment (100µM) start time. Linear regression was fit to the resultant data (R 2 = 0.86, P < 0.05, for DTG A & B). The mortalitymorbidity for DTG exposure was highest with early pre-gastrulation exposures (1-3hpf), differed significantly over time (1-3 hpf vs 5-8hpf, T-test P = 0.001), and was lowest at 6-8hpf. Co-exposure of folic acid (FA, 60ng/mL) with DTG (100µM) results in rescue from developmental toxicity. Folate exposure rescues DTG toxicity in zebrafish embryos. A) Embryos were statically exposed beginning at 3 post fertilization (hpf) to dolutegravir (DTG), folic acid (FA), or DTG + FA. High developmental toxicity (80-100%) were observed with DTG treatment, with rescue by co-exposure to folate (0% mortality). B) Embryos were statically exposed beginning at 3-hour post fertilization to DTG, FA or DTG + FA. Tables report number of dead and normal embryos for clutches; embryos in different clutches have different parents and are therefore biological replicates.
Supplemental
Supplemental Figure 2
Calcium Modifies Cellular Folate Binding
The impact of cations on folate binding in the presence of DTG was initially tested in HELA cells. Images of HELA cells exposed to 20µM DTG, 50nM FA-680 (red), and Hoechst 3342 (blue, live-nuclei) in buffer (1X DPBS, 1% FBS). The impact of A) potassium, B) magnesium, C) iron, D) control, and E) calcium are shown at 24hrs. Potassium showed a nonsignificant increase in FA-680 signal. Iron and magnesium showed significant increased FA-680 signal (* P<0.05). Calcium showed the largest increase in cellular FA-680 binding compared to control (**** P<0.0001).
